The Question Isn't Whether FDA Can Move Faster. It's Whether You Can.
What FDA's proposed Expedited IND Pilot reveals about operational readiness for clinical trial sponsors.
Why This Matters
FDA’s proposed Expedited IND Pilot has generated considerable interest because of its potential to accelerate early clinical development. But after listening to the FDA webinar on August 6 introducing the pilot, one message stood out above all others: this initiative is not really about changing the statutory 30-day IND review period.
Instead, it’s about improving everything that happens around it.
For clinical trial sponsors, that is important. While few organizations will participate in the pilot itself, the operational principles behind it are relevant to everyone. The questions FDA is asking about earlier collaboration, better information, and more efficient development are the same questions many sponsors are already asking themselves.
Understanding those signals may be more valuable than understanding the pilot.
The Question Everyone is Asking
When FDA announced the proposed Expedited IND Pilot as part of Operation TrailBlazer, most of the discussion immediately focused on one question.
Will FDA review INDs faster?
It’s an understandable assumption. The initiative is designed to accelerate early clinical development, and headlines naturally gravitated toward shorter timelines and faster studies.
But if you watched FDA’s webinar introducing the pilot, you probably noticed something different. Agency leaders repeatedly emphasized that the statutory 30-day IND review period is not changing. That point was made several times throughout the presentation.
So if the review clock isn’t changing, what exactly is? The answer may be much more significant than the timeline itself.
Rather than focusing on making FDA reviewers work faster, the agency is exploring ways to improve how sponsors and regulators work together before, during, and immediately after an IND submission. The emphasis is on earlier dialogue, stronger submissions, better coordination, and reducing unnecessary delays that do not improve scientific quality or participant safety.
In other words, FDA isn’t simply asking: “How can we review INDs faster?”
It’s asking: “How can we make the entire development process work better?”
For sponsors, that shift in thinking is worth paying attention to.
Looking Beyond the Review Clock
One of the most interesting aspects of the webinar was that FDA spent relatively little time talking about the 30-day review period itself.
Instead, speakers described the realities of early drug development:
- Applications that require multiple rounds of clarification.
- Information that arrives later than expected.
- Activities that occur sequentially simply because that’s how they’ve always been done.
- Teams waiting on one another before moving forward.
These are not new challenges. Every sponsor has experienced some version of them.
Throughout the webinar, FDA described opportunities to improve the overall development process by encouraging earlier interactions, iterative engagement, and allowing appropriate activities to move in parallel rather than one after another.
The distinction FDA drew was between activities necessary to protect participants and support sound science, and delays that add time without adding value. As FDA emphasized during the webinar, the purpose of the IND process remains exactly the same.
- Protecting research participants.
- Ensuring sound science.
- Maintaining appropriate regulatory oversight.
Those principles are not changing. What FDA is questioning is whether some of the work surrounding those principles could be done differently.
A Different Way of Thinking About Efficiency
One idea appeared repeatedly throughout the discussion: removing work that doesn’t add value.
At first glance, that may sound like a simple efficiency initiative. It isn’t. It’s a quality initiative.
Every hour spent preparing information that is never used…
Every unnecessary handoff…
Every duplicate review…
Every delay caused by incomplete communication…
All of that represents time that could instead be spent improving study design, strengthening scientific discussions, or addressing meaningful risks..
That philosophy aligns with a broader evolution we’ve been watching across clinical research.
- Quality by Design encourages organizations to focus on building quality into development rather than inspecting it in later.
- ICH E6(R3) encourages sponsors to concentrate oversight on activities that are important to participant safety and data reliability.
- Risk-based quality management asks organizations to distinguish meaningful risks from operational noise.
The proposed Expedited IND Pilot reflects many of those same principles. Not because FDA says these initiatives are identical. But because they all ask a similar question.
Where is effort creating value, and where is it simply creating work?
That may ultimately become one of the most important operational questions sponsors ask over the coming years.
The Bigger Opportunity May Be Operational
As the webinar continued, another theme became increasingly clear. Many of the challenges FDA described were not regulatory challenges. They were operational ones.
And none of those issues are unique to FDA. They exist across nearly every development organization. That’s one of the reasons this webinar felt so relevant, even for sponsors who may never participate in the pilot.
The questions FDA is asking mirror questions many organizations are already confronting internally. Those are operational questions long before they become regulatory ones.
Parallel Doesn't Mean Simpler
One concept discussed throughout the webinar was the opportunity to move certain activities in parallel instead of sequentially.
At first glance, that sounds like an obvious improvement. If activities can happen simultaneously, development should move faster. In practice, however, working in parallel is often more demanding than working sequentially, as it requires:
- Greater confidence that decisions are being made using accurate and complete information
- Clear ownership across multiple functions
- Stronger governance
- And perhaps most importantly, visibility
Working in parallel therefore requires something sequential processes can sometimes mask: visibility across functions. Without it, parallel activity can increase confusion, duplicate effort, and introduce new risks.
Although the webinar focused on early regulatory engagement, the operational principles extend far beyond the IND process.
Whether organizations are preparing for regulatory interactions, managing global studies, or overseeing complex vendor ecosystems, the underlying challenge remains remarkably consistent:
Can the organization make confident decisions using the right information at the right time?
What This Means for Trial Sponsors
This is where we believe the webinar becomes particularly valuable. It’s easy to watch the presentation and conclude that the Expedited IND Pilot is only relevant to a small number of organizations selected to participate.
We came away with a different perspective. The pilot may be limited. The questions it raises are not.
Every sponsor can benefit from asking:
- How easily does critical information move across our organization?
- Where do unnecessary delays occur before important decisions are made?
- Are our governance processes helping teams make decisions, or unintentionally slowing them down?
- Do our external partners have the visibility they need?
- Could we confidently support earlier, more iterative engagement with regulators if the opportunity arose?
Those questions are becoming increasingly important regardless of whether a sponsor ever submits an application through this pilot.
Visibility Becomes Increasingly Important
One theme running quietly beneath the webinar was the importance of information flow. FDA repeatedly discussed submission quality, communication, collaboration, and earlier engagement. All of those depend on one thing. Visibility.
Organizations cannot improve decisions if critical information remains fragmented across functions, systems, vendors, or study teams.
This is one reason we believe topics such as Clinical Study Data Flow Maps have become increasingly relevant. Understanding how critical information moves across a study helps organizations identify unnecessary delays, clarify responsibilities, and strengthen oversight before problems become visible downstream.
Similarly, as sponsors evaluate how they demonstrate oversight, the conversation extends beyond having complete TMF records. Increasingly, it’s about being able to explain how important decisions were made, why they were made, and whether they were supported by appropriate evidence. That’s the same philosophy behind Risk-Proportionate TMF Oversight, where the emphasis shifts from simply counting records to demonstrating meaningful oversight.
Neither concept was the focus of the webinar. But both naturally support the operational direction FDA described.
This Isn't Happening in Isolation
Perhaps the biggest takeaway from the webinar wasn’t the pilot itself. It was recognizing that this initiative doesn’t stand alone. Across Quality by Design, risk-based quality management, ICH E6(R3), Operation TrailBlazer, and now the proposed Expedited IND Pilot, we continue to see greater emphasis on focusing effort where it creates value.
These initiatives have different purposes and should not be treated as a single regulatory strategy. But the direction is worth noticing: less emphasis on administrative activity and greater emphasis on quality, collaboration, informed decision-making, and meaningful oversight.
That may be a much bigger story than the pilot itself.
Conclusion
The proposed Expedited IND Pilot may ultimately affect a relatively small number of organizations directly. Its broader message, however, has relevance across the industry. FDA’s discussion raises important questions about how clinical development could become more collaborative, better coordinated, and more efficient without compromising quality or participant protection.
For sponsors, that means the most important question may not be whether FDA can move faster. It may be whether our own organizations are prepared to work differently.
If Operation TrailBlazer signals anything, it is that the future of clinical research will depend less on doing more work and more on ensuring that the work we do truly improves quality, strengthens oversight, and supports better decisions.
And that is a conversation every sponsor can begin having today.
